| Basics |
Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
|
| IPO Date: |
October 31, 2008 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$614.65M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.12 | 3.33%
|
| Avg Daily Range (30 D): |
$0.08 | 2.54%
|
| Avg Daily Range (90 D): |
$0.08 | 2.40%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.17M |
| Avg Daily Volume (30 D): |
.94M |
| Avg Daily Volume (90 D): |
.81M |
| Trade Size |
| Avg Trade Size (Sh.): |
220 |
| Avg Trade Size (Sh.) (30 D): |
116 |
| Avg Trade Size (Sh.) (90 D): |
114 |
| Institutional Trades |
| Total Inst.Trades: |
220 |
| Avg Inst. Trade: |
$1.71M |
| Avg Inst. Trade (30 D): |
$.96M |
| Avg Inst. Trade (90 D): |
$.98M |
| Avg Inst. Trade Volume: |
.5M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.27M |
| Avg Closing Trade (30 D): |
$1.09M |
| Avg Closing Trade (90 D): |
$1.09M |
| Avg Closing Volume: |
639.48K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-.38
|
$-.07
|
$-.38
|
|
Diluted EPS
|
$-.38
|
$-.07
|
$-.38
|
|
Revenue
|
$ 6.17M
|
$ 1.57M
|
$ 6.17M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -69.92M
|
$ -12.53M
|
$ -69.92M
|
|
Operating Income / Loss
|
$ -76.32M
|
$ -13.93M
|
$ -76.32M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 10.05M
|
$ 4.48M
|
$ 10.05M
|
|
PE Ratio
|
|
|
|
|
